[one week Jun] step pharmaceutical also faced the "crisis", and its products were shut down; the first provincial linkage 4 + 7; drugstores included in the "volume purchase"; 8 medical institutions were reported

Last week's highlights: 1 The five ministries and commissions encouraged clinics to carry out, and the medical pattern changed greatly; 2 Heavy weight! Drugstores are included in the "volume procurement"; 3 Fujian takes the lead in the province wide linkage 4 + 7: no need for drugs will not account for the proportion of drugs; 4 Step pharmaceutical has ushered in a "crisis" again, and its products have been stopped On May 13, the national health and Health Commission, the national development and Reform Commission, the Ministry of finance, the Ministry of human resources and social security and the State Health Insurance Bureau formulated the opinions on carrying out pilot projects to promote the development of clinics, and will carry out pilot projects to promote the development of clinics in 10 cities including Beijing, Shanghai and Shenyang from 2019 to 2020 The following changes should be noted: changing the examination and approval of clinic setting to the record system management; doctors practicing in clinics should obtain the qualification of intermediate and above professional titles Doctors are encouraged to run specialist clinics full-time or part-time According to the wishes of the clinic, it can be incorporated into the construction of medical consortia, and different specialists can be encouraged to hold joint clinics Clinics are encouraged to be included in the scope of medical institutions that can provide contracted services for family doctors, through the provision of personalized contracted services The prices of medical services provided by clinics are self pricing The above changes may be a major opportunity for pharmaceutical companies According to statistics, 80% of the current sales volume of pharmaceutical enterprises in the society comes from the hospital market, and the spread of this policy may encourage the doctors in the hospital to gradually go out of the system, and then the patients will also be shunted, which will indirectly affect the sales volume of drugs in the hospital market In view of this, the layout of the terminal market is another way for enterprises to reform their policies In 2019, the anti-corruption campaign of medicine continued Eight medical institutions were notified and nearly 6 million medical insurance funds were recovered On May 15, the state health insurance bureau reported the third batch of cases of fraudulent medical insurance funds, involving eight medical institutions Eight hospitals involved were punished in varying degrees and nearly 6 million yuan of medical insurance funds were recovered However, this is only one of the common actions taken by the National Health Insurance Bureau to fight against corruption in medicine this year At the same time, the state attaches great importance to anti-corruption work and has issued a number of regulatory measures On April 23, at the second incorruptible work conference of the State Council, the premier requested that governments at all levels conscientiously implement the plan of overall and strict governance of the party, deepen the construction of a clean and honest government and the anti-corruption work, and effectively promote the sustainable and healthy development of the economy and society The anti-corruption work must be persistent and unremitting In August last year, the national health and Health Commission, together with the Ministry of industry and information technology, the State Administration of market supervision and administration, the State Medical Security Bureau, the State Administration of traditional Chinese medicine and other nine departments issued a notice In addition to making it clear that the unfair competition such as commercial bribery should be strengthened, medical institutions should also establish and improve the hospital reception process of medical representatives to ensure that the hospital behaviors of medical representatives can be recorded, monitored and disclosed With the strengthening of the supervision of local medical insurance bureaus, illegal behaviors such as insurance fraud and kickback will be further curbed, and the supervision of medical insurance funds will be normalized and sustained As a result, some people in the industry predict that the special treatment of this year's unhealthy trend will be launched in the second half of the year On the one hand, it will create a good environment for the smooth promotion of 4 + 7, and at the same time, it is normal to crack down on corruption in the field of pharmaceutical purchase and sale At the same time, the registration system of medical representatives, which has attracted much attention, may be promoted nationwide this year The industry is so hot! On May 15, the drugstore was incorporated into the "volume purchase", and Shandong Province drug centralized purchase network issued a document, pointing out that private medical institutions and chain retail drugstores (hereinafter referred to as "agreement pharmaceutical institutions") managed by medical insurance agreement can purchase drugs online through Shandong Province drug centralized purchase platform In principle, the total quantity of drugs (excluding Chinese herbal pieces) in the catalogue of basic medical insurance purchased online by the agreement pharmaceutical institutions applying to participate in the online purchase shall not be less than 60% of the total quantity of drugs in the catalogue of basic medical insurance used (sold) by the unit The purchase price of drugs shall be negotiated independently by the contracted medical institutions and the production and operation enterprises It belongs to the medicine settled by the medical insurance fund The actual sales price is higher than the net price obtained from the bidding price of the purchase platform, and the medical insurance shall be paid according to the price not higher than the bidding price With the "group" centralized purchase of drugs in hospitals, the price of the same drugs in pharmacies is much higher than that in hospitals That is to say, the price of the same drugs is different In order to get cheap drugs, patients go to the hospital to get drugs, which not only increases the time cost of patients, but also increases the pressure of medical resources In this situation, Shandong Province will include drugstores in "volume procurement" or expected At the beginning of the announcement of the results of 4 + 7, many voices believed that the price reduction rate of the selected pharmaceutical enterprises was as high as 96% and more than half of the product specifications were reduced by more than 50% Under such a large price reduction rate, these selected pharmaceutical enterprises had to reduce costs, and the first one to be flushed might be the sales team and promotion personnel of the corresponding selected varieties On the one hand, it may be difficult to bear the operating cost of the sales team due to the sharp price reduction of selected drugs and the reduction of gross profit; on the other hand, the consumption of 4 + 7 selected drugs in public hospitals in 11 pilot cities has been guaranteed in advance, so pharmaceutical enterprises do not need the original promotion personnel to promote the sales However, this is not the case The winning enterprises have not made any action to cut the sales staff, and the sales teams of some enterprises have increased There are several reasons: the first country organizes centralized drug procurement, which is the first batch in terms of time, and the follow-up progress is uncertain; the second drug enterprise may take measures to crush the cost while facing low price, and the cost pressure may not be as large as expected; the third, winning the bid may pay more attention to an opportunity to expand the scale, which needs to be considered by others Can welcome the variety of market space, reserve sales personnel Fujian takes the lead in the province wide linkage 4 + 7: no need for drug meetings or no proportion of drugs on May 14, Fujian drug procurement center organized 4 + 7 selected enterprises and some commercial companies to hold a symposium According to the meeting, the provincial linkage 4 + 7 selected price Among them, the selected varieties are preferred to be online, and the varieties supplied at the bid price of 4 + 7 can be online directly; based on 60% of the consumption of public medical institutions in Fujian Province in 2018, the period is one year, and the bid winning enterprises are required to ensure the procurement volume In addition, in principle, ensure the completion of the basic purchase volume, and the proportion of the use of the selected drugs shall not be less than 50% of the purchase volume of the same generic drug this year At the same time, at the use level, a tripartite purchase and sale contract shall be signed, and at the same time, all medical institutions shall not affect the use of the selected varieties due to the proportion of drugs, drug affairs meeting and other reasons This also means that the selected varieties can enter the hospital directly without the approval of the pharmaceutical Council And hospitals should not control the clinical use of the selected varieties because of the proportion of drugs Up to now, some non-4 + 7 pilot areas, such as Jiangxi and Hebei, have started the 4 + 7 price linkage, but now Fujian has also carried out the provincial linkage Whether the information of other provinces' linkage will be released in succession remains to be seen Enterprise information step pharmaceutical is facing a "crisis" again, and its products are stopped buying Step pharmaceutical announced in the evening of December 12 that it received a post audit inquiry letter from the Shanghai Stock Exchange on the 2018 annual report of Shandong step Pharmaceutical Co., Ltd., asking the company to explain 13 aspects of problems such as the efficacy of related products of traditional Chinese medicine injection, whether there are adverse reactions or quality problems reported by the media, and asking the annual audit accountant to express his opinions on relevant issues On May 13, BofA opened 5.77% lower at 25.49 yuan / share At about 9:30, a wave of large orders escaped BofA fell 9.98% to 24.35 yuan / share, then the decline narrowed slightly As of the press release of the interface, step pharmaceutical reported 24.69 yuan / share, down 8.72% However, the storm goes far beyond that Today, media reported that Zhengzhou top three hospital issued a notice, saying that after the discussion of the expert group, the relevant varieties of the group stopped purchasing and selling from now on At the same time, according to the information pushed by the medical representatives of wechat public platform, in addition to Zhengzhou, there is also a large hospital in Nanyang, Henan Province, which stopped purchasing all products under Steph pharmaceutical after discussion by the expert group Xianju pharmaceutical's kickback was reported by its real name Jiangsu health and Health Commission sent a letter to examine the fact that Zhejiang Xianju pharmaceutical was reported by its real name for suspected drug kickback, and Jiangsu health and Health Commission sent a letter to examine it The real name reporting / real name whistleblowing has been reported recently, which is to increase the sales volume of Mometasone Furoate Nasal Spray (50ug, 60 press / box), and give 15 yuan / box rebate to some doctors in Jiangsu The health and Health Commission of Jiangsu Province requires it to set up the health and Health Administration Department of each district and City Health Commission and the risk office to carefully check and report the results of the check before May 31 The problem of medical commercial bribery is a common one, which leads to the abuse of the law and the vicious competition, and it has been involved for a long time At present, China's medical reform has entered a critical period and deep-water area It has been one of the key contents of the pharmaceutical industry to control pharmaceutical kickbacks and increase the anti-corruption of medicine, and the relevant policies are also being issued Harbin Pharmaceutical Group replied to the inquiry of Shanghai Stock Exchange On April 24, Shanghai stock exchange required Harbin Pharmaceutical Group to conclude the situation of comparable companies in the contract industry and the change of production and sales volume of specific products in terms of the company's business situation, the operating revenue of API industry and the product structure of anti infective products Specifically, the reasons and rationality of the sharp drop of API revenue scale and the negative gross profit margin of the company's nutritional supplements, cold medicine and other products were explained The reason for the high rate and its rationality For the inquiry of Shanghai Stock Exchange, Harbin Pharmaceutical Group finally explained the reasons for the sharp decline of pharmaceutical industry income in recent years, including the impact of environmental protection policy, the impact of bidding price reduction, the impact of medical reform policy, the aging of product structure and internal factors It can be seen that similar enterprises of Harbin Pharmaceutical Group have a more and more difficult life for API enterprises due to the increasing pressure of environmental protection As a large-scale manufacturer of API in China, Harbin Pharmaceutical Group said in its reply to Shanghai stock exchange that it is speeding up channel adjustment, changing marketing mode and gradually increasing the proportion of medical distribution business It can be said that 2019 will be a crucial transformation year for Harbin Pharmaceutical Group Information source: yaozhi.com, cypress blue, yaomaitong, e-medicine manager, Sina medicine, pharmaceutical economic news and other statements: this point of view only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.